NASDAQ:YMAB Y-mAbs Therapeutics (YMAB) Stock Price, News & Analysis $13.82 -0.17 (-1.22%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$13.27▼$14.4250-Day Range$9.95▼$15.3952-Week Range$4.69▼$20.90Volume319,566 shsAverage Volume357,147 shsMarket Capitalization$615.96 millionP/E RatioN/ADividend YieldN/APrice Target$21.14 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Y-mAbs Therapeutics alerts: Email Address Y-mAbs Therapeutics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.88 Rating ScoreUpside/Downside53.0% Upside$21.14 Price TargetShort InterestBearish13.04% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.45Based on 3 Articles This WeekInsider TradingSelling Shares$503,164 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($0.57) to ($0.38) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.74 out of 5 starsMedical Sector385th out of 910 stocksPharmaceutical Preparations Industry171st out of 426 stocks 4.4 Analyst's Opinion Consensus RatingY-mAbs Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.88, and is based on 6 buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageY-mAbs Therapeutics has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Y-mAbs Therapeutics' stock forecast and price target. Previous Next 0.0 Short Interest Percentage of Shares Shorted13.04% of the float of Y-mAbs Therapeutics has been sold short.Short Interest Ratio / Days to CoverY-mAbs Therapeutics has a short interest ratio ("days to cover") of 16.9, which indicates bearish sentiment.Change versus previous monthShort interest in Y-mAbs Therapeutics has recently increased by 3.00%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldY-mAbs Therapeutics does not currently pay a dividend.Dividend GrowthY-mAbs Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for YMAB. Previous Next 1.4 News and Social Media Coverage News SentimentY-mAbs Therapeutics has a news sentiment score of 0.45. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Y-mAbs Therapeutics this week, compared to 3 articles on an average week. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Y-mAbs Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $503,164.00 in company stock.Percentage Held by Insiders21.50% of the stock of Y-mAbs Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions70.85% of the stock of Y-mAbs Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Y-mAbs Therapeutics' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Y-mAbs Therapeutics are expected to grow in the coming year, from ($0.57) to ($0.38) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Y-mAbs Therapeutics is -28.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Y-mAbs Therapeutics is -28.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioY-mAbs Therapeutics has a P/B Ratio of 6.46. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Y-mAbs Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Paradigm PressKamala’s Dirty Election Move… RevealedAccording to former advisor to the CIA, the Pentagon and the White House Jim Rickards… Kamala and her puppet masters are planning this dirty election move… Click here now and learn how to prepare. About Y-mAbs Therapeutics Stock (NASDAQ:YMAB)Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow. The company is also developing DANYELZA for the treatment of patients with second-line relapsed osteosarcoma and is in Phase II clinical study; GD2-SADA, which is in Phase I clinical trial for the treatment of GD2 positive solid tumor; and Omburtamab, a murine monoclonal antibody for the treatment of central nervous system/leptomeningeal metastases from neuroblastoma, as well as SADA PRIT technology platform. In addition, it is engages in the developing of CD38-SADA and GD2-GD3 Vaccine. The company has a license agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize licensed products. Y-mAbs Therapeutics, Inc. was incorporated in 2015 and is headquartered in New York, New York.Read More YMAB Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart YMAB Stock News HeadlinesAugust 28, 2024 | insidertrades.comY-mAbs Therapeutics, Inc. (NASDAQ:YMAB) COO Sells $73,450.00 in StockSeptember 6 at 7:30 AM | globenewswire.comY-mAbs Presents Neuroblastoma Research on Naxitamab and SADA PRIT Technology Platform at AACR Special Conference on Advances in Pediatric Cancer ResearchSeptember 7, 2024 | Golden Crest (Ad)Biden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial independence and security.September 3, 2024 | globenewswire.comY-mAbs to Participate in Upcoming Investor Conferences in SeptemberAugust 30, 2024 | americanbankingnews.comY-mAbs Therapeutics, Inc. (NASDAQ:YMAB) COO Joris Wilms Sells 5,000 SharesAugust 14, 2024 | finanznachrichten.deY-mAbs Therapeutics, Inc.: Y-mAbs Reports Second Quarter 2024 Financial Results and Recent Corporate DevelopmentsAugust 14, 2024 | seekingalpha.comY-mAbs Therapeutics, Inc. (YMAB) Q2 2024 Earnings Call TranscriptAugust 14, 2024 | markets.businessinsider.comBuy Rating Affirmed for Y-Mabs Therapeutics Amid Solid R&D Prospects and Resilient Financial PerformanceSeptember 7, 2024 | Golden Crest (Ad)Biden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial independence and security.August 14, 2024 | markets.businessinsider.comBuy Rating on Y-mAbs Therapeutics: Robust Sales Growth and Strong Pipeline ProspectsAugust 14, 2024 | benzinga.comAssessing Y-mAbs Therapeutics: Insights From 5 Financial AnalystsAugust 12, 2024 | fool.comWhy Y-mAbs Therapeutics Stock Got Mashed on MondayAugust 12, 2024 | marketwatch.comY-mAbs Therapeutics Shares Drop on Downbeat 2Q, GuidanceAugust 12, 2024 | seekingalpha.comRevisiting Y-mAbs After The Summer Oncology Meeting (Rating Upgrade)August 12, 2024 | investorplace.comYMAB Stock Earnings: Y-mAbs Therapeutics Misses EPS, Misses Revenue for Q2 2024August 12, 2024 | globenewswire.comY-mAbs Reports Second Quarter 2024 Financial Results and Recent Corporate DevelopmentsAugust 9, 2024 | msn.comY-mAbs Therapeutics, Inc. (YMAB): One of Caligan Partners' Top Holdings Now?August 9, 2024 | msn.comY-mAbs Therapeutics, Inc. (YMAB): One of Caligan Partners’ Top Holdings Now?See More Headlines Receive YMAB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Y-mAbs Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/12/2024Today9/07/2024Next Earnings (Estimated)11/11/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:YMAB CUSIPN/A CIK1722964 Webwww.ymabs.com Phone(646) 885-8505FaxN/AEmployees150Year FoundedN/APrice Target and Rating Average Stock Price Target$21.14 High Stock Price Target$26.00 Low Stock Price Target$11.00 Potential Upside/Downside+53.0%Consensus RatingModerate Buy Rating Score (0-4)2.88 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)($0.49) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-21,430,000.00 Net Margins-28.44% Pretax Margin-27.70% Return on Equity-24.88% Return on Assets-18.78% Debt Debt-to-Equity RatioN/A Current Ratio2.92 Quick Ratio2.72 Sales & Book Value Annual Sales$84.82 million Price / Sales7.26 Cash FlowN/A Price / Cash FlowN/A Book Value$2.14 per share Price / Book6.46Miscellaneous Outstanding Shares44,570,000Free Float34,448,000Market Cap$615.96 million OptionableOptionable Beta0.70 The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free Report Key ExecutivesMr. Thomas Gad (Age 53)Founder, Chief Business Officer & Vice Chairman Comp: $1.05MMr. Bo Kruse (Age 51)Executive VP, Secretary, Treasurer & CFO Comp: $685.02kMs. Susan Smith (Age 53)Senior VP & Chief Commercial Officer Comp: $710kMr. Michael Rossi (Age 53)CEO, President & Director Mr. Joris Wiel Jan Wilms (Age 50)Senior VP & COO Dr. Torben Lund-Hansen M.Sc. (Age 73)Ph.D., Senior VP & CTO Dr. Steen Lisby M.D. (Age 60)M.Sc., Senior VP & Chief Scientific Officer Comp: $393.99kMs. Courtney DuganVice President of Investor RelationsDr. Vignesh Rajah M.B.A. (Age 59)MBBS, Senior VP & Chief Medical Officer Comp: $406.27kMore ExecutivesKey CompetitorsAurinia PharmaceuticalsNASDAQ:AUPHHeron TherapeuticsNASDAQ:HRTXAmarinNASDAQ:AMRNMersana TherapeuticsNASDAQ:MRSNGeneration BioNASDAQ:GBIOView All CompetitorsInsiders & InstitutionsJoris WilmsSold 5,000 sharesTotal: $73,450.00 ($14.69/share)Point72 Asset Management L.P.Sold 1,168,155 shares on 8/19/2024Ownership: 0.818%Millennium Management LLCBought 67,233 shares on 8/15/2024Ownership: 0.797%AQR Capital Management LLCSold 15,915 shares on 8/15/2024Ownership: 0.050%Squarepoint Ops LLCBought 74,452 shares on 8/14/2024Ownership: 0.288%View All Insider TransactionsView All Institutional Transactions YMAB Stock Analysis - Frequently Asked Questions How have YMAB shares performed this year? Y-mAbs Therapeutics' stock was trading at $6.82 on January 1st, 2024. Since then, YMAB stock has increased by 102.6% and is now trading at $13.82. View the best growth stocks for 2024 here. How were Y-mAbs Therapeutics' earnings last quarter? Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) announced its quarterly earnings results on Monday, August, 12th. The company reported ($0.21) earnings per share for the quarter, missing analysts' consensus estimates of ($0.13) by $0.08. The business earned $22.80 million during the quarter, compared to analyst estimates of $23.09 million. Y-mAbs Therapeutics had a negative net margin of 28.44% and a negative trailing twelve-month return on equity of 24.88%. When did Y-mAbs Therapeutics IPO? Y-mAbs Therapeutics (YMAB) raised $80 million in an IPO on Friday, September 21st 2018. The company issued 5,300,000 shares at $14.00-$16.00 per share. BofA Merrill Lynch, Cowen and Canaccord Genuity served as the underwriters for the IPO and BTIG was co-manager. Who are Y-mAbs Therapeutics' major shareholders? Top institutional investors of Y-mAbs Therapeutics include Dimensional Fund Advisors LP (1.10%), Point72 Asset Management L.P. (0.82%), Millennium Management LLC (0.80%) and Acadian Asset Management LLC (0.74%). Insiders that own company stock include Biotech Aps Wg, Johan Wedell-Wedellsborg, Bo Kruse, Thomas Gad, Vignesh Rajah and Joris Wilms. View institutional ownership trends. How do I buy shares of Y-mAbs Therapeutics? Shares of YMAB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Y-mAbs Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Y-mAbs Therapeutics investors own include Bank of Hawaii (BOH), InterDigital (IDCC), STAG Industrial (STAG), Corbus Pharmaceuticals (CRBP), CTI BioPharma (CTIC), Nabriva Therapeutics (NBRV) and Occidental Petroleum (OXY). This page (NASDAQ:YMAB) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredThese 5 stocks could soar after November 4thHow to Trade this Crazy Election Year? Simple – Just Focus on These 5 stocks… Now available – a free report...StockEarnings | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Y-mAbs Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Y-mAbs Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.